What to Expect When Taking PLUVICTO
Before treatment with PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)
A PSMA PET scan will check for PSMA+ cancer in your body
If you have already been treated with other anticancer treatments and your doctor determines that PLUVICTO is an appropriate treatment, he/she will refer you to a radiation oncologist or nuclear medicine treatment facility to receive PLUVICTO.
- A team of doctors will be working together to manage care of your PSMA+ metastatic castration-resistant prostate cancer
- Laboratory tests will be performed within 3 days before your first treatment with PLUVICTO
During treatment with PLUVICTO
PLUVICTO is given once every 6 weeks for up to 6 treatments, depending on how your body responds to the treatment
You will be kept at a distance from other patients.
You should drink a lot of fluids and urinate as frequently as possible to eliminate the product from your body.
After treatment with PLUVICTO
Be sure to follow instructions given by your health care provider.
Limit close contact (less than 3 feet) with other people in your household for 2 days.
- Limit close contact with children or pregnant women for 7 days
Sleep separately from other people at a distance of at least 3 feet for 3 days after treatment.
- Sleep separately from children for 7 days or pregnant women for 15 days
- Refrain from sexual activity for 7 days
Use effective contraception during treatment with PLUVICTO and for 14 weeks after the final dose. All radiopharmaceuticals, including PLUVICTO, have the potential to cause fetal harm.
Drink a lot of fluids and urinate as frequently as possible.
Contact your health care provider if you experience low levels of blood cell count symptoms such as fever, chills, sore throat, mouth ulcers, weakness, tiredness, pale skin, spontaneous bleeding or bruising, or shortness of breath; or kidney problem symptoms such as passing urine less often than usual or passing much smaller amounts than usual.
PSMA+, prostate-specific membrane antigen positive.
